Evidence map›Paper›PMID 30685922›Full record

ArticleZhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology2019

[AKR1B10 inhibitor enhances the inhibitory effect of sorafenib on liver cancer xenograft].

Y Y Jin, C Han, N Geng, Y R Li, L Y Zheng, W J Zhu, Y W Li, Z Y An, L R Zhao, J Y Wang and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. [Aldo-keto reductase family 1 B10 participates in the regulation of hepatoma cell cycle through p27/p-Rb signaling pathway].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2020
    Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Y Y JinDepartment of Infectious Disease, Shengjing Hospital of China Medical University, Shenyang 110022, China.
C Han
N Geng
Y R Li
L Y Zheng
W J Zhu
Y W Li
Z Y An
L R Zhao
J Y Wang
X G Dou
H Bai

Funding

Liaoning Provincial Science and Technology Planning Project 2013225021"Thirteenth Five-Year Plan" Major National Science and Technology Major Projects 2017ZX10202203-008
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Carcinoma, HepatocellularHeterograftsLiver NeoplasmsOxidoreductases Acting on Aldehyde or Oxo Group DonorsAdultAldo-Keto ReductasesAnimalsAntineoplastic AgentsCell Line, TumorCell ProliferationHumansMiceMice, NudeProtein Kinase InhibitorsSorafenibXenograft Model Antitumor AssaysAkr1b10 protein, mouseAldo-Keto ReductasesAntineoplastic AgentsOxidoreductases Acting on Aldehyde or Oxo Group DonorsProtein Kinase InhibitorsSorafenibAldo-keto reductase 1B10Carcinoma, hepatocellularCombined treatmentEpalrestatHepatocellular carcinoma xenograftSorafenib

Identifiers

PMID30685922
PMCPMC12769024

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.